Saturday 17 October 2026
Export INTS’s income statement to Excel — free account
Intensity Therapeutics Inc.
INTS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 65.9%, free cash flow grew 4.72% and total debt fell 34.7%, each against the same quarter a year earlier.
3.35
0.03
−0.89%
Follow INTS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 50.25 | 43.25 | 4.63 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 286.00 | 219.50 | 79.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 16 | — | 7 | 7 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EBT | — | — | — | (5) | (6) | (8) | (8) | (11) | (16) | (12) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | (5) | (6) | (8) | (8) | (11) | (16) | (12) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.41) | (22.11) | (28.94) | (55.59) | (34.50) | (29.25) | (8.56) | |||||
| Cash flow | — | — | — | (0.34) | (19.69) | (25.03) | (40.15) | (20.91) | (27.37) | (6.81) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.34) | (19.69) | (25.03) | (40.15) | (20.91) | (27.37) | (6.81) | |||||
| Book value | — | — | — | 0.59 | 30.94 | 4.82 | (37.38) | 38.20 | 5.25 | 8.76 | |||||
| Shares, m | — | — | — | 13 | 0 | 0 | 0 | 0 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (5) | (7) | (5) | (7) | (15) | (9) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (4) | (5) | (7) | (5) | (7) | (15) | (9) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 8 | 8 | 1 | (5) | 12 | 2 | 11 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 4 | 0 | 0 | 0 | |||||
| Net debt | — | — | — | (8) | (9) | (4) | (1) | (15) | (2) | (12) | |||||
| Shareholders’ equity | — | — | — | 8 | 8 | 1 | (5) | 13 | 3 | 12 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (62.96) | (102.77) | (217.46) | (124.52) | (147.37) | (122.92) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,366.58) | (22,007.35) | |||||
| ROE | — | — | — | 0.00 | 312.47 | 154.16 | 63.76 | 1,225.41 | (202.34) | (156.90) | |||||
Negative figures in brackets.
Charts ten years each
Intensity Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $11.6M | — (loss-making) | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| CLRB Cellectar Biosciences, Inc. | $11.2M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INTS Intensity Therapeutics Inc. | $11.0M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | |
| PHIO Phio Pharmaceuticals Corp. | $10.8M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $10.7M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $10.7M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $11.4M | — | — | −43.33% | — | +13.10% | 0.00% | 0.00% |
Intensity Therapeutics Inc. (INTS) key facts
- Intensity Therapeutics Inc. (INTS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, INTS traded at $3.35, a market capitalization of $11.0 million.
- Return on equity was −156.9% and debt-to-equity 0.01.